Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Shots:

• The approval is based on two P-III studies evaluating the diagnostic results of Gadavist enhanced cardiac MRI to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD
• Gadobutrol-enhanced cardiac MRI demonstrated efficacy in global clinical studies and provide details about the functions of the heart muscles to support the management of patients with CAD
• Gadavist is an approved contrast agent in >100 countries including the US, EU, Japan for multiple indications i.e, CE-MRA, CE-MRI of the liver and kidneys, CNS and all body regions

Click here to read full press release/ article | Ref: Bayer | Image: Office Snapshots